达拉非尼和曲美替尼引发的放射性回忆性皮炎：一例报告
Radiation recall dermatitis with dabrafenib and trametinib: A case report.
作者信息
Yilmaz Mesut, Celik Ugur, Hascicek Seyhan
机构信息
Medical Oncology Department, Bakirköy Dr. Sadi Konuk Training and Research Hospital, Istanbul 34144, Turkey.
Dermatology Department, Medipol Kosuyolu Hospital, Istanbul 34134, Turkey.
出版信息
World J Clin Cases. 2020 Feb 6;8(3):522-526. doi: 10.12998/wjcc.v8.i3.522.
BACKGROUND
Radiation recall dermatitis has been defined as the "recalling" by skin of previous radiation exposure in response to the administration of certain response-inducing drugs. Although the phenomenon is relatively well known in the medical world, an exact cause has not been documented.
CASE SUMMARY
Here, we report the rare occurrence of radiation recall dermatitis after palliative radiotherapy for bone metastases in a metastatic melanoma patient treated with a combination of dabrafenib and trametinib.
CONCLUSION
We present a case of radiation recall dermatitis after completion of palliative radiotherapy while being treated with a combination of dabrafenib and trametinib. This is a very rare toxic event, and there is insufficient data to describe prevention strategies. Increased awareness and reporting of cases will help to better explain the association between targeted therapy and the radiation recall phenomenon.
背景
放射性回忆性皮炎被定义为皮肤对先前辐射暴露的“回忆”，以响应某些诱导反应的药物给药。尽管这种现象在医学界相对广为人知，但确切原因尚未有文献记载。
病例摘要
在此，我们报告了一名转移性黑色素瘤患者在接受姑息性骨转移放疗后，接受达拉非尼和曲美替尼联合治疗时罕见地发生了放射性回忆性皮炎。
结论
我们报告了一例在接受达拉非尼和曲美替尼联合治疗期间完成姑息性放疗后发生放射性回忆性皮炎的病例。这是一种非常罕见的毒性事件，且没有足够的数据来描述预防策略。提高对病例的认识和报告将有助于更好地解释靶向治疗与放射性回忆现象之间的关联。
Zotero 插件